

Savings Analysis: FELRA

Based on 12 Months of Historical Claims (November 2021 - October 2022)
November 28, 2022

Alternate Funding Breakdown:

Alternate Funding Status	Claims	Plan Cost	Alternate Funding %
Alternate Funding	1,852	\$ 9,836,508	36%
Variable Funding	71	1,811,432	7%
<i>Not Available</i>	163,934	15,728,287	57%
Grand Total	165,857	\$ 27,376,227	100%

Alternate Funding by Product:

Specialty Brands	Claims	Plan Cost	% of Total Spend by Drug
Humira	307	\$ 1,954,015	20%
Enbrel	135	637,774	6%
Revlimid	30	628,162	6%
Biktarvy	139	592,024	6%
Stelara	29	578,490	6%
Triumeq	81	278,556	3%
Tremfya	24	233,895	2%
Genvoya	42	232,434	2%
Skyrizi	16	222,636	2%
Ofev	20	217,672	2%
Ibrance	18	194,801	2%
Kesimpta	32	192,319	2%
Imbruvica	12	181,121	2%
Otezla	57	177,333	2%
Xyrem	12	167,728	2%
Taltz	33	166,063	2%
Dupixent	49	162,905	2%
Stribild	38	160,066	2%
Xeljanz	43	159,582	2%
Oxbryta	21	148,040	2%
Vumerity	22	131,283	1%
Lonsurf	16	128,341	1%
Aubagio	20	123,410	1%
Odefsey	27	113,885	1%
Xtandi	12	112,498	1%
Rebif	17	110,107	1%
Symtuza	21	107,407	1%
Orencia	28	105,047	1%
Rinvoq	21	91,725	1%
Creon	34	87,118	1%
Vemlidy	40	83,799	1%
Xolair	51	79,967	1%

Savings Analysis: FELRA

Based on 12 Months of Historical Claims (November 2021 - October 2022)

November 28, 2022

Alternate Funding by Product:

Specialty Brands	Claims	Plan Cost	% of Total Spend by Drug
Mayzent	12	\$ 78,978	1%
Descovy	26	78,398	1%
Betaseron	9	77,255	1%
Epclusa	3	72,221	1%
Benlysta	27	68,588	1%
Repatha	75	67,961	1%
Gilenya	9	60,993	1%
Simponi	10	58,557	1%
Stivarga	4	58,412	1%
Calquence	5	53,846	1%
Prezista	23	48,055	0%
Vosevi	3	48,040	0%
Tymlos	22	45,537	0%
Ziextenzo	7	43,200	0%
Prezcobix	14	41,760	0%
Aptiom	22	41,248	0%
Nucala	8	36,107	0%
Cabometyx	2	33,255	0%
Harvoni	1	31,374	0%
Dovato	12	30,670	0%
Isentress	15	25,168	0%
Tivicay	11	20,840	0%
Fasenra	6	19,951	0%
Aimovig	31	19,000	0%
Retacrit	7	18,821	0%
Orilissa	7	18,146	0%
Velphoro	4	18,111	0%
Edurant	12	15,581	0%
Prolia	11	14,727	0%
Selzentry	3	13,372	0%
Lynparza	1	10,751	0%
Venclexta	1	5,014	0%
Aristada	2	2,371	0%
Grand Total	1,852	\$ 9,836,508	100%
% of Total Claims	1.1%		

Savings Analysis: FELRA

Based on 12 Months of Historical Claims (November 2021 - October 2022)
November 28, 2022

Variable Funding by Product ⁽¹⁾:

Specialty Brands	Claims	Plan Cost	% of Total Spend by Drug
Ravicti ⁽²⁾	12	\$ 1,081,055	60%
Tagrisso	34	422,242	23%
Thiola Ec	10	190,179	10%
Retevmo	5	38,745	2%
Inflectra	4	30,022	2%
Sucraid	2	24,805	1%
Cabenuva	2	13,256	1%
Prevymis	2	11,128	1%
Grand Total	71	\$ 1,811,432	100%
% of Total Members & Claims	0.0%		

Cost Avoidance Fee:

Annualized Alternate Funding Amount: **\$ 11,647,940**

Potential Annual Plan Savings: **\$ 8,931,219**

Potential Monthly Plan Savings: **\$ 744,268**

Notes

1. Variable funding refers to specialty brands where funding sources exist, but may be variable based on specific requirements or limited to less than the full cost of the drug. These brands are more complex than most specialty medications and may be determined on a case-by-case basis per the manufacturer.

2. Payer Matrix Fee is capped at \$75,000 per member per year.